Related Experiment Video

Updated: Jul 3, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome

Donatella Colaizzo1, Lucio Amitrano, Giovanni L Tiscia

  • 1aAtherosclerosis and Thrombosis, Casa Sollievo della Sofferenza, S. Giovanni Rotondo, Italy.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|July 5, 2008
PubMed

Insights

The JAK2 V617F mutation is prevalent in Budd-Chiari syndrome patients, indicating a link to myeloproliferative diseases. Testing for this mutation can identify at-risk individuals for developing these conditions.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Myeloproliferative diseases are significant risk factors for Budd-Chiari syndrome.
  • Budd-Chiari syndrome involves hepatic venous outflow obstruction, often linked to thrombotic events.

Purpose of the Study:

  • To investigate the prevalence of the JAK2 V617F mutation in patients diagnosed with Budd-Chiari syndrome.
  • To assess the association between the JAK2 V617F mutation and the presence of myeloproliferative diseases in these patients.
  • To determine the utility of JAK2 V617F mutation detection for identifying patients at risk for myeloproliferative diseases.

Main Methods:

  • Genotyping analysis was performed on 32 patients with Budd-Chiari syndrome to detect the JAK2 V617F mutation.
  • Patient medical records were reviewed to ascertain diagnoses of myeloproliferative diseases before or at the time of venous thrombotic events.

Main Results:

  • The JAK2 V617F mutation was identified in 11 out of 32 patients (34.4%) with Budd-Chiari syndrome, predominantly in a heterozygous state.
  • A higher proportion of patients with the JAK2 V617F mutation (72.7%) had a pre-existing or concurrent diagnosis of myeloproliferative diseases compared to those without the mutation (28.6%).
  • Three patients with the JAK2 V617F mutation did not have a diagnosed myeloproliferative disease at the time of the study.

Conclusions:

  • The JAK2 V617F mutation is frequently observed in patients with Budd-Chiari syndrome, suggesting a strong association with myeloproliferative neoplasms.
  • Detecting the JAK2 V617F mutation is a valuable tool for identifying patients with Budd-Chiari syndrome who have or are at risk of developing myeloproliferative diseases.
  • This genetic marker aids in risk stratification and potentially early diagnosis of myeloproliferative diseases in the context of Budd-Chiari syndrome.

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Sex-linked Disorders01:43

Sex-linked Disorders

Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...